MINNEAPOLIS, Nov. 14 /PRNewswire-FirstCall/ -- Biotel Inc. (OTC
Bulletin Board: BTEL) announced strong sales and earnings for its first
quarter ended September 30, 2007. The Company had net earnings of $170,000,
or $0.06 per diluted share, on revenues of $2,751,000. This compares to a
net loss of $11,000, or $0.00 per diluted share, on revenues of $2,424,000
for the first quarter of last year.

Highlights for the first quarter are as follows:

-- 13.5% revenue growth, year over year

-- Gross margin of 45.6%, up from 40.7% a year ago

-- Operating expenses reduced to 36.1% of revenues from 40.8% last year

-- Operating margin of 9.5% versus a loss a year ago

-- Net margin of 6.2% versus a loss a year ago

-- Strong balance sheet with no long-term debt

-- Stockholders' equity of $4,115,000, up 4.6% year over year

"We had a strong first quarter beginning our fiscal year with year over
year growth in product and service revenues and improved margins," Biotel
President and CEO Steve Springrose said. "Compared to the first quarter of
fiscal 2007, we had increased sales of our Braemar cardiac event recorders,
Holter devices, liposuction and other medical devices. Revenues from our
Agility 24/7cardiac monitoring services for clinical research continued to
grow rapidly. Biotel continues to serve as a development partner to medical
corporations seeking new devices and clinical research services, in keeping
with our long-term strategy."

In the first quarter, Biotel held operating expenses flat from a year
ago, even with a 10.3% increase in Research and Development. "We continued
to put emphasis on R&D to expand our proprietary technology across our
product spectrum," Springrose commented. "Most importantly, we received FDA
510(k) clearance in October to market our Braemar ER900 Wireless Event
Recorder. This is a cardiac looping recorder and cellular transmitter, the
first in a series of Braemar wireless products that will transmit cardiac
information through cellular networks without patient interaction. We
believe this will give us a leadership position in a new era of cardiac
monitoring technology."

(Date:12/8/2016)... San Francisco, California (PRWEB) , ... December 08, 2016 , ... ... health coaches, has raised an $18M Series B led by Canvas Ventures . ... use the capital to scale its mobile platform to serve more consumers who are ...

(Date:12/8/2016)... ... December 08, 2016 , ... The Dan Carlisle Agency, ... Jefferson County, is announcing the launch of a charity drive to raise support ... homeless women and children in Birmingham has grown steadily since the 1980’s, and ...

(Date:12/8/2016)... , ... December 08, 2016 , ... The Compretta Insurance ... and residential clients in and around the Hancock County area, is announcing the launch ... County Food Pantry. , The Hancock County Food Pantry has worked for more than ...

(Date:12/7/2016)... (PRWEB) , ... December 07, 2016 , ... DrugDev ... the announcement that it is one of the early adopters completing EU-U.S. Privacy Shield ... is designed to provide companies on both sides of the Atlantic with a mechanism ...

(Date:12/7/2016)... Kenosha, Wisconsin (PRWEB) , ... December 07, 2016 , ... ... the extraordinary new MedMaster™ MPCNGX . The MPCNGX is a multi-function, sealed, LED ... the right amount of light where and when it’s needed. , A ...

(Date:12/8/2016)... , Dec. 8, 2016 IRIDEX Corporation (NASDAQ: ... offer newly issued shares of common stock, $0.01 par value ... an underwritten public offering. The final terms of the Offering ... of pricing, and there can be no assurance as to ... IRIDEX expects to use the net proceeds it will receive ...

(Date:12/8/2016)... -- Global Interventional Radiology Market: Scope and Methodology ... market analyzes the current and future prospects of ... summary, including a market snapshot that provides overall ... research is a combination of primary and secondary ... research efforts along with information collected from telephonic ...

(Date:12/8/2016)... 2016 Eli Lilly and Company (NYSE: ... 3 EXPEDITION3 trial at the 9 th Clinical ... solanezumab did not meet the primary endpoint in the ... people with mild dementia due to Alzheimer,s disease (AD), ... for the treatment of mild dementia due to AD. ...